StockNews.AI
EW
StockNews.AI
5 days

Edwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm

1. The Portnoy Law Firm initiates an investigation into Edwards for possible securities fraud. 2. Edwards cut its 2024 revenue guidance for its TAVR platform after disappointing Q2 results. 3. Stock dropped 31.34% following the revenue guidance cut and TAVR utilization concerns. 4. Three acquisitions announced by Edwards signal awareness of TAVR's decelerating growth. 5. Investors are urged to contact the law firm to potentially recover losses.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock price decline following poor earnings indicates strong market reaction. Historical context shows that such declines often lead to diminishing investor confidence and prolonged volatility.

How important is it?

The investigation could lead to legal challenges affecting investor confidence and stock price.

Why Short Term?

The immediate effect stems from the ongoing investigation and market reaction, which could stabilize in the medium to long term depending on future performance.

Related Companies

EWMEDPABTHLSBAX
Investors can contact the law firm at no cost to learn more about recovering their losses ​ LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Edwards Lifesciences Corporation (“Edwards” or “the Company”) (NYSE:EW) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Edwards investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. On July 24, 2024, Edwards reported financial results for the second quarter of fiscal 2024 that fell below expectations and, notably, cut its full-year 2024 revenue guidance for its Transcatheter Aortic Valve Replacement (“TAVR”) platform. The Company attributed the TAVR slowdown to the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” Investors understood this to mean that the growth of new procedures—including Edwards’ own Transcatheter Mitral and Tricuspid Therapies (“TMTT”)—strained hospital structural heart teams, leading to underutilization of TAVR despite the Company’s repeated assertion of a significantly undertreated patient population. Edwards also announced three acquisitions during the quarter to bolster treatments alternative to TAVR, further suggesting that the Company was aware of the TAVR platform’s decelerating growth. Following these disclosures, Edwards’ stock price fell sharply, declining from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024—a drop of approximately 31.34% in a single trading day. Please visit our website to review more information and submit your transaction information. The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barslesley@portnoylaw.com310-692-8883www.portnoylaw.com Attorney Advertising

Related News